InvestorsHub Logo
Followers 177
Posts 24463
Boards Moderated 11
Alias Born 04/03/2002

Re: Don'tDrinkTheKoolAid post# 1607

Tuesday, 06/26/2018 12:03:42 PM

Tuesday, June 26, 2018 12:03:42 PM

Post# of 1900
Celldex Therapeutics, Inc. (CLDX) Analyst Opinion

Celldex Therapeutics, Inc. has a consensus outperform rating from 5 Wall Street analysts, and the number of shares currently sold short amount to at least 6.01% of shares outstanding. The stock sank -20.98% last month and is down -81.64 this year. Wall Street is only getting more bullish on the stock, with 2 of analysts who cover CLDX having a buy-equivalent rating. Analysts have placed a $4.13 price target on Celldex Therapeutics, Inc., suggesting a 694.23% gain from recent close. It’s currently trading about -84.01% below its 52-week high.
Link:
https://postanalyst.com/2018/06/25/hot-stocks-among-investors-celldex-therapeutics-inc-cldx-achillion-pharmaceuticals-inc-achn/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CLDX News